目的:探讨FOLFOX方案治疗胃癌的疗效及对血清干扰素-γ(INF-γ)和白细胞介素-4(IL-4)水平的影响。方法:选择我院2011年1月至2014年1月收治的胃癌患者80例,按随机数字表法平均分为两组,研究组及对照组各40例,以3周为1个疗程,治疗3个疗程。研究组患者给予FOLFOX方案治疗,对照组患者给予ELF化疗方案,3个疗程后,比较两组患者治疗有效率,同时比较两组患者治疗前后血清INF-γ和IL-4水平变化及不良反应发生情况。结果:3个疗程后,研究组患者治疗有效率为57.5%,明显高于对照组37.5%,比较差异具有统计学意义(P<0.05)。两组患者治疗后血清INF-γ水平及INF-γ/IL-4值较治疗前明显升高,而IL-4水平较治疗前明显下降,且研究组患者两种细胞因子水平改善程度均明显优于对照组,比较差异具有统计学意义(P<0.05)。研究组患者白细胞减少、血小板下降及恶心呕吐不良反应发生率分别为22.5%、7.5%及27.5%,与对照组25.0%、10.0%及32.5%,比较差异无统计学意义(P>0.05)。结论:FOLFOX方案治疗胃癌效果显著,可有效改善患者机体免疫水平,提高抗肿瘤效果,值得临床推广应用。 Objective: To investigate the efficacy of FOLFOX regimen in treatment of gastric cancer and its effect on serum levels of interferon-γ (INF-γ) and interleukin-4 (IL-4). Methods: Eighty patients with gastric cancer admitted to our hospital from January 2011 to January 2014 were randomly divided into two groups according to the random number table method. The study group and the control group included 40 patients each. One course of treatment was 3 weeks. 3 courses. Patients in the study group were treated with FOLFOX regimen, while those in the control group were given ELF regimen. After three courses of treatment, the treatment efficacies were compared between the two groups. Serum levels of INF-γ and IL-4 and adverse reactions were compared between the two groups before and after treatment Happening. Results: After three courses of treatment, the effective rate of treatment in study group was 57.5%, which was significantly higher than that in control group (37.5%). The difference was statistically significant (P <0.05). Serum levels of INF-γ and INF-γ / IL-4 in both groups were significantly higher than those before treatment, while levels of IL-4 were significantly lower than those before treatment in both groups, and the levels of both cytokines in study group were significantly improved Better than the control group, the difference was statistically significant (P <0.05). The incidences of leukopenia, thrombocytopenia and nausea and vomiting in the study group were 22.5%, 7.5% and 27.5%, respectively, which were not significantly different from those in the control group (25.0%, 10.0% and 32.5%, P> 0.05). Conclusion: The FOLFOX regimen is effective in treating gastric cancer, which can effectively improve the immune level of patients and improve the anti-tumor effect, which is worthy of clinical application.